On 16 March 2023, the FDA approved dabrafenib (Tafinlar, Novartis) in combination with trametinib (Mekinist, Novartis) for pediatric patients aged 1 year and older with low-grade glioma (LGG) harboring a BRAF V600E mutation and requiring systemic therapy (NCT02684058). The gene discussed is BRAF; the disease is low grade glioma.